Gerald H. Friedland, M.D.

Professor of Medicine and Epidemiology
Director, AIDS Program
Yale New-Haven Hospital and Yale University

Research Interests

Dr. Friedland's major research interests are in the provision of HIV care to vulnerable populations and clinical trials of anti-retroviral agents, including adherence to HIV therapies and pharmacologic interaction studies between methadone and buprenorphine and antiretroviral agents. He is the Principal Investigator of the Yale AIDS Clinical Trials Unit. Dr. Friedland is also involved in studies of HIV and risk reduction among HIV seropositives in clinical care and, most recently, in studies on the integration of care and treatment of tuberculosis and HIV disease in resource limited settings, notably South Africa. His group has uncovered the epidemic of XDR TB in South Africa and is working on epidemiologic, clinical and mycobacteriologic studies in this area.

Education

MD, New York University, 1964

BA, Columbia College, 1959

Fellowship: Bellevue Hospital

Recent Publications

• Friedland G, Abdool Karim S, Abdool Karim Q, Lalloo U, Jack C, Gandhi N and El Sadr W: The Utility of Tuberculosis Directly Observed Therapy (DOT) programs as sites for access and provision of antiretroviral therapy in resource limited settings. Clinical Infectious Diseases 2004; 38 (Suppl 5):S421-S428.
• Jack C, Lalloo U, Abdool Karim Q, Abdool l Karim S, El-Sadr W, Cassol S, Friedland G: A Pilot Study of Once Daily Antiretroviral Therapy Integrated with Tuberculosis Directly Observed Therapy (TBDOT) In A Resource Limited Setting. Journal of Acquired Immune Deficiency Syndromes 2004; 36:929-934.
• Kozal, MJ, Amico R, Chiarella J, Schreibman T, Cornman D, Fisher WA, Fisher JD, Friedland G: Antiretroviral resistance and high-risk transmission behavior among HIV-positive patients in clinical care. AIDS 2004; 18:2185-2189.
• Altice FL, Mezger J, Hodges J, Bruce RD, Marinovich A, Walton M, Springer SA, Friedland G: Developing a Directly Administered Antiretroviral Therapy Intervention for HIV-Infected Drug Users: Implications for Program Replication. Clinical Infectious Diseases 2004; 38(Suppl5):S376-387.
• Cassol E, Page T, Mosam A, Friedland G, Jack C, Lalloo U, Kopetka J Patterson B, Esterhuizen T, Coovadia H, Therapeutic Response of HIV-1 Subtype C in African Patients Coinfected with either Mycobacterium tuberculosis or Human Herpesvirus The Journal of Infectious Diseases 2005;191:324-332
• Bruce RD, Altice FL, Gourevitch MG, Friedland GH, A Review of Pharmacokinetic Drug Interactions Between Opioid Agonist Therapy and Antiretroviral Medications: Implications and Management for Clinical Practice, Journal of Acquired Immune Deficiency Syndromes 2006; 41(5):563-572.
• Kozal MJ, Amico KR, Chiarella J Cornman Fisher W, Fisher J Friedland G, Population Based and Longitudinal Study of Sexual Behavior and Multidrug Resistant HIV Among Patients in Clinical Care, eJournal of the International AIDS Society, 2006; 8(2):72-79.
• Friedland G, HIV Medication Adherence, The intersection of biomedical, behavioral and social science research and clinical practice, Journal of Acquired Immune Deficiency Syndromes, 2006, 14 October; 43 Supplement 1:S3-S9.
• Mannheimer S, Morse E, Matts J, Andrews L, Child C, Schmetter B, Friedland G, Sustained Benefit From a Long-Term Antiretroviral Adherence Intervention: Results of a Large Randomized Clinical Trial. Journal of Acquired Immune Deficiency Syndromes. 2006, December 1; 43 Supplement 1:S41-S47.
• Gandhi N Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, Friedland G, Extensively Drug-Resistant Tuberculosis (XDR TB) as a Cause of Death among TB/HIV Co-infected Patients in a Rural Area in South Africa Lancet 2006; 368:1575-80.
• Friedland G, Tuberculosis, Drug Resistance and HIV/AIDS; Triple Threat. Current Infectious Diseases Reports 2007;9:252-261)

Contact

Campus Address
135 College Street
Suite 323

E-mail
gerald.friedland@yale.edu

Office Phone
(203) 688-6959

Fax
(203) 737-4051